Regeneron Pharmaceuticals, Inc.
Corporate Headquarters
777 Old Saw Mill River Road
Tarrytown
New York
10591
United States
Tel: 914-847-7000
Website: https://www.regeneron.com/
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Stock Symbol: REGN
Stock Exchange: NASDAQ
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Learn more about how our team produces the highest-quality treatments for patients at https://www.regeneron.com/.
1400 articles about Regeneron Pharmaceuticals, Inc.
-
Educational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Dermatitis
9/18/2019
Understand AD program brings together a team of experts to help a teen with severe atopic dermatitis (AD) and his parents navigate the disease
-
Regeneron Debuts on Prestigious Dow Jones Sustainability World Index of Most Sustainable Companies
9/17/2019
Regeneron Pharmaceuticals, Inc. announced that the company was added to the Dow Jones Sustainability World Index for the first time.
-
In an ongoing battle between Regeneron Pharmaceuticals and Sanofi versus Amgen over PCSK9 inhibitors to treat high cholesterol, a U.S. district court invalidated Amgen’s patents for Repatha.
-
U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9
8/28/2019
Court rules in favor of Regeneron and Sanofi in ongoing Praluent® (alirocumab) patent litigation
-
Clinical Catch-up for August 12-16
8/19/2019
As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines. -
Regeneron Announces Upcoming Investor Conference Presentation - Aug. 15, 2019
8/15/2019
Regeneron Pharmaceuticals, Inc. will webcast its presentation at the Morgan Stanley 17th Annual Global Healthcare Conference at 8:10 a.m. Eastern Time on Monday, September 9, 2019.
-
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
8/14/2019
Regeneron Pharmaceuticals, Inc. announced positive pivotal Phase 3 results for evinacumab, an investigational angiopoietin-like 3 antibody, in patients with homozygous familial hypercholesterolemia.
-
In the trial, evinacumab showed a 49% decrease in LDL cholesterol from baseline compared to placebo, which showed a 2% increase.
-
FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe
8/13/2019
EYLEA is the only anti-VEGF approved to treat four retinal conditions with a single dose strength prefilled syring
-
Today it was announced that the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals’ prefilled syringes for Eylea.
-
PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths
8/12/2019
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Company was informed by study investigators that a randomized, controlled trial evaluating four investigational therapies for Ebola virus infection was stopped early because REGN-EB3 was superior to ZMapp in preventing death.
-
Now that July has come and gone, the U.S. Food and Drug Administration is back to work approving drugs. This week marks three PDUFA target action dates, although one has already been rejected and another hit a snag that doesn’t appear to affect the decision date.
-
Clinical Catch-up for August 5-9
8/12/2019
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look. -
Regeneron Reports Second Quarter 2019 Financial and Operating Results
8/6/2019
Regeneron Pharmaceuticals, Inc. announced financial results for the second quarter of 2019 and provided a business update.
-
Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis
8/6/2019
Regeneron Pharmaceuticals, Inc. and Sanofi announced that a pivotal Phase 3 trial evaluating Dupixent® to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints.
-
Dupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
8/6/2019
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission extended marketing authorization for Dupixent® in the European Union to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
-
The two companies will seek approval for the biologic as a treatment for severe atopic dermatitis in children ages six to 11.
-
According to a BioSpace poll, approximately 86% of life science respondents are on the verge of job burnout. Are you one of the 86%? Does this mean you need to start looking for a new job? This is definitely one of your options. Start here to look at all of the great opportunities out there in t...
-
The Fortune 500 list is compiled of the 500 U.S.-based companies that generate the most revenue. In the latest ranking, one dozen biopharma companies were included, with one, Johnson & Johnson, breaking into the top 50 and only four in the top 100.
-
Regeneron Announces the 2019 Winners of the Regeneron Prize for Creative Innovation
7/18/2019
Regeneron Pharmaceuticals, Inc. announced the winners of the seventh annual Regeneron Prize for Creative Innovation.